Article
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
mBio - 26 Oct 2021
Haslwanter Denise, Dieterle M Eugenia, Wec Anna Z, O'Brien Cecilia M, Sakharkar Mrunal, Florez Catalina, Tong Karen, Rappazzo C Garrett, Lasso Gorka, Vergnolle Olivia, Wirchnianski Ariel S, Bortz Robert H, Laudermilch Ethan, Fels J Maximilian, Mengotto Amanda, Malonis Ryan J, Georgiev George I, Quiroz Jose A, Wrapp Daniel, Wang Nianshuang, Dye Kathryn E, Barnhill Jason, Dye John M, McLellan Jason S, Daily Johanna P, Lai Jonathan R, Herbert Andrew S, Walker Laura M, Chandran Kartik, Jangra Rohit K
Abstract excerpt
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) of the spike (S) protein. Variants of concern (VOC) carrying mutations in the RBD or other regions of S reduce the effectiveness of many nAbs and vaccines by evading neutralization. Therefore, therapies that are less susceptible to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.